Abstract

Background

The current standard of care (SOC) for whole breast radiotherapy (WBRT) in the US is conventional tangential photon fields. Advanced WBRT techniques may provide similar tumor control and better normal tissue sparing, but it is controversial whether the medical benefits of an advanced technology are significant enough to justify its higher cost.

Objective

To analyze the cost-effectiveness of six advanced WBRT techniques compared with SOC.

Methods

We developed a Markov model to simulate health states for one cohort of women (65-year-old) with early-stage breast cancer over 15 years after WBRT. The cost-effectiveness analyses of field-in-field (FIF), hybrid intensity modulated radiotherapy (IMRT), full IMRT, standard volumetric modulated arc therapy (STD-VMAT), multiple arc VMAT (MA-VMAT), non-coplanar VMAT (NC-VMAT) compared with SOC were performed with both tumor control and radiogenic side effects considered. Transition probabilities and utilities for each health state were obtained from literature. Costs incurred by payers were adopted from literature and Medicare data. Quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) were calculated. One-way sensitivity analyses and probabilistic sensitivity analyses (PSA) were performed to evaluate the impact of uncertainties on the final results.

Results

FIF has the lowest ICER value of 1,511 $/QALY. The one-way analyses show that the cost-effectiveness of advanced WBRT techniques is most sensitive to the probability of developing contralateral breast cancer. PSAs show that SOC is more cost effective than almost all advanced WBRT techniques at a willingness-to-pay (WTP) threshold of 50,000 $/QALY, while FIF, hybrid IMRT and MA-VMAT are more cost-effective than SOC with a probability of 59.2%, 72.3% and 72.6% at a WTP threshold of 100,000 $/QALY, respectively.
Conclusions
FIF might be the most cost-effective option for WBRT patients at a WTP threshold of 50,000 $/QALY, while hybrid IMRT and MA-VMAT might be the most cost-effective options at a WTP threshold of 100,000 $/QALY.

Background
Breast cancer has the highest incidence rate among women in the United States besides skin cancer (www.cancer.org). Lumpectomy is commonly performed for patients with early-stage breast cancer, and whole breast radiotherapy (WBRT) after lumpectomy can improve local control and overall survival [1].

The current standard of care (SOC) for whole breast radiation therapy (WBRT) in the US and in our clinic is conventional tangential photon fields [2, 3]. Other advanced technologies had been proposed for WBRT and shown auspicious results, such as field-in-field (FIF) technique [4, 5], hybrid Intensity modulated radiation therapy (IMRT) [6–8], fixed beam IMRT [9, 10], standard volumetric modulated arc therapy (STD-VMAT) [11], multiple arc VMAT (MA-VMAT) [12]. Non-coplanar VMAT (NC-VMAT) has been shown to improve organs at risk (OAR) dosimetry for post-mastectomy breast cancer [13], but has not been investigated for WBRT. These advanced technologies are superior to SOC in improving the dose homogeneity within the target volume and reduce therapeutic dose to radiosensitive organs, but may increase low-dose cloud which could cause higher risk of radiogenic side effects [14, 15].

It has been reported that the cost of breast cancer treatments is around $16.5 billion in the United States in 2010, which is higher than any other type of cancer, and is projected to reach $20 billion by 2020 [16]. Although more advanced radiotherapy technologies may improve dosimetric outcomes under certain circumstances, their much higher cost may not justify their advantages. There have been some cost-effectiveness studies comparing partial breast irradiation and WBRT [17–19], but the comprehensive cost-effectiveness comparison among advanced WBRT techniques including costs of radiogenic side effects is still lacking.

The aim of this study was to analyze the cost-effectiveness of various WBRT techniques including conventional SOC, FIF, hybrid IMRT, IMRT, STD-VMAT, MA-VMAT and NC-VMAT. The conventional SOC was used as the reference for modality comparisons. Both tumor coverage and late side effects (cardiac toxicity and secondary cancers) after WBRT were included in the analyses.

Methods
Decision model
A Markov model (Fig 1) was designed using TreeAge Pro (Williamstown, MA) to simulate the clinical history of 65-year-old postmenopausal women with early-stage breast cancer who received lumpectomy and subsequent WBRT with a prescribed dose of 50 Gy in 25 fractions. All patients start with no evidence of disease (NED) after WBRT, and transition afterwards to one of the four states (distant metastasis, local recurrence, late radiogenic side effects, and death from other causes) in 1-year cycles. The patients could also die from breast cancer, which is mainly caused by distance metastasis, and die from radiogenic side effects.

A 15-year horizon after radiotherapy was analyzed in the model since study has shown the improvement in local control and survival due to radiotherapy during this time period [1].
The incremental cost effectiveness ratio (ICER) was expressed in terms of cost per life-year gained according to the following formula:

$$ ICER = \frac{C_1 - C_0}{E_1 - E_0} $$

where $C_0$ and $E_0$ are the cost and quality adjusted life year (QALY) for SOC technique, and $C_1$ and $E_1$ are the cost and QALY for other WBRT techniques. Willingness-to-pay (WTP) thresholds of $50,000/ QALY and $100,000/QALY [20, 21] were used to determine whether a WBRT technique is cost-effective.

**Model data input**

All transition probabilities and utilities for SOC were extracted from published literature [1, 22–26] and are shown in Table 1.

The costs of different WBRT techniques from payer perspective were based on local hospital Medicare charges, including costs for physician consultant, dosimetry, treatment fractions, physics quality assurance etc., and are shown in Table 2, and the costs of treating 3 radiogenic late side effects were extracted from literature and are also included in Table 2. Only direct medical costs are considered in this study. The advanced techniques contain radiation intensity modulation, which requires a specific charge for the equipment and extra workload for quality assurance performed by medical physicists. This is the major reason that advanced RT techniques are more expensive than SOC. Costs and utilities were discounted at an annual rate of 3% [32].
Since the clinical data of tumor control or radiogenic late effects after advanced WBRT techniques were largely incomplete, we assumed probabilities of local recurrence and distant metastasis for advanced WBRT to be the same as those after SOC WBRT, and calculated probabilities of radiogenic late effects for those techniques using well-defined risk models including lifetime attributable risk (LAR) for second cancers [39] and risk for coronary events (RCE) [40, 41] as shown in Table 3. We assumed that all lung and cardiac events start from year 11

### Table 1. Annual transition probability and utility for the 65-year-old patient cohort who received SOC WBRT.

| Parameters             | Years       | Value (%) (range) | Reference |
|------------------------|-------------|-------------------|-----------|
| Probability            |             |                   |           |
| Local Recurrence       | 0–5         | 1.46              | [1]       |
|                        | 6–10        | 0.54              |           |
|                        | 11–15       | 0.06              |           |
| NED to metastasis      | 0–5         | 12.25             | [22]      |
|                        | 6–10        | 7.75              |           |
|                        | 11–15       | 7.75              |           |
| Metastasis to Death    | 0–5         | 23.2              | [23]      |
|                        | 6–15        | 14.0              |           |
| Death from other causes| 65–70 (age)| 1.46              | [27]      |
|                        | 71–75 (age) | 1.71              |           |
|                        | 76–80 (age) | 3.53              |           |
| Death due to lung toxicity | 11–15   | 0.078             | [25]      |
| Death due to heart toxicity | 11–15   | 0.53              | [26]      |
| Death due to CL breast toxicity | 6–15 | 2.12              | [1]       |
| Utility                |             |                   |           |
| NED                    | 0–5         | 0.734             | [28]      |
|                        | 6–10        | 0.716             |           |
|                        | 11–15       | 0.675             |           |
| Cardiac toxicity       | 11–15       | 0.57(0.54–0.61)   | [29]      |
| CL Breast cancer       | 6–15        | 0.54(0.48–0.55)   | [30]      |
| Lung cancer            | 11–15       | 0.50 (0.39–0.56)  | [30, 31]  |
| Recurrence             | 0–5         | 0.66              | [28]      |
|                        | 6–10        | 0.65              |           |
|                        | 11–15       | 0.61              |           |
| Metastasis             | 0–5         | 0.44              | [28]      |
|                        | 6–10        | 0.43              |           |
|                        | 11–15       | 0.41              |           |

https://doi.org/10.1371/journal.pone.0248220.t001

Since the clinical data of tumor control or radiogenic late effects after advanced WBRT techniques were largely incomplete, we assumed probabilities of local recurrence and distant metastasis for advanced WBRT to be the same as those after SOC WBRT, and calculated probabilities of radiogenic late effects for those techniques using well-defined risk models including lifetime attributable risk (LAR) for second cancers [39] and risk for coronary events (RCE) [40, 41] as shown in **Table 3**. We assumed that all lung and cardiac events start from year 11

### Table 2. Treatment costs.

| Treatment                  | Cost (range)         | Reference                  |
|----------------------------|----------------------|----------------------------|
| WBRT (SOC/FIF)             | $12,140              | Based on Medicare charge   |
| WBRT (Hybrid IMRT)         | $15,293              | Based on Medicare charge   |
| WBRT (VMAT/ IMRT)          | $17,438              | Based on Medicare charge   |
| Cardiac toxicity           | $11,570±3405         | [29, 33]                   |
| CL breast cancer           | $14,494±1199         | [34]                       |
| Lung cancer                | $20,577±2740         | [35–37]                    |
| local recurrence           | $20,879              | [38]                       |
| Metastasis                 | $13,627              | [38]                       |

https://doi.org/10.1371/journal.pone.0248220.t002
after radiotherapy [40, 42], while contralateral breast events start from year 6 after radiother-
apy [43].

The model validity was assessed by comparing 15-year survival results with predicted
results from CancerMath, which is the latest web-based prognostic tool that includes conven-
tional radiotherapy as part of treatment for breast cancer patients [45, 46].

**Sensitivity analyses**

A series of one-way sensitivity analyses were performed over a wide range of assumptions for
probabilities, utilities, and treatment costs of radiogenic side effects for six advanced WBRT
techniques versus SOC.

Probability sensitivity analyses (PSA) were also performed to assess the uncertainty and
robustness of the model by assigning specific distributions for model parameters, where the
probabilities, utilities, and costs of radiogenic side effects were varied simultaneously across
their distributions using Monte Carlo simulation. Recommended by Briggs et al. [47], we used
beta distribution for transition probabilities and utilities estimates, and used gamma distribu-
tions for cost parameters. The cost-effectiveness acceptability was calculated based on the
result of 100,000 simulations for each WBRT technique at different WTP thresholds.

**Results**

The external validation of our model was assessed for 65-year-old women with early-stage
breast cancer. Our model predicted a 15-year overall survival rate of 53.3% and breast cancer
mortality rate of 21.7%, and CancerMath calculated an overall survival rate of 55.0% and breast

| Side effect                  | Probability (%) | Range (%) |
|------------------------------|-----------------|-----------|
| SOC cardiac toxicity         | 1.24            | 0.80–2.03 |
| SOC CL breast cancer         | 0.38            | 0.13–1.39 |
| SOC lung cancer              | 0.22            | 0.18–0.28 |
| FIF cardiac toxicity         | 1.15            | 0.80–1.97 |
| FIF CL breast cancer         | 0.38            | 0.18–0.71 |
| FIF lung cancer              | 0.22            | 0.18–0.31 |
| Hybrid IMRT cardiac toxicity | 1.16            | 0.77–1.88 |
| Hybrid IMRT CL breast cancer | 0.35            | 0.12–1.33 |
| Hybrid IMRT lung cancer      | 0.20            | 0.16–0.27 |
| IMRT cardiac toxicity        | 1.14            | 0.74–1.78 |
| IMRT CL breast cancer        | 0.32            | 0.71–0.71 |
| IMRT lung cancer             | 0.20            | 0.14–0.27 |
| STD-VMAT cardiac toxicity    | 1.16            | 0.69–1.77 |
| STD-VMAT CL breast cancer    | 0.27            | 0.17–0.54 |
| STD-VMAT lung cancer         | 0.20            | 0.18–0.29 |
| NC-VMAT cardiac toxicity     | 1.05            | 0.65–1.51 |
| NC-VMAT CL breast cancer     | 0.27            | 0.17–0.78 |
| NC-VMAT lung cancer          | 0.18            | 0.13–0.25 |
| MA-VMAT cardiac toxicity     | 1.03            | 0.65–1.52 |
| MA-VMAT CL breast cancer     | 0.26            | 0.15–0.39 |
| MA-VMAT lung cancer          | 0.17            | 0.10–0.24 |

https://doi.org/10.1371/journal.pone.0248220.t003
cancer mortality rate of 19.5%. These comparisons suggest that our model’s predictions are similar to real clinical outcomes.

Table 4 shows baseline ICERs for all six WBRT techniques compared with SOC. Among six techniques that been analyzed, FIF shows the lowest ICER of $1,511/QALY while IMRT shows highest ICER of $121,087/QALY.

The one-way analyses (S1 Fig) show that the cost-effectiveness of all six advanced WBRT techniques is most sensitive to the probability of developing contralateral breast cancer. S2 Fig shows cost-effectiveness acceptability curves for various advanced WBRT techniques at different willingness to pay thresholds. The probabilities of being more cost-effective than SOC for six WBRT techniques are shown in Table 5. At a WTP threshold of $50,000/QALY, except FIF which has a 58.9% probability of being more cost-effective, none of the other five WBRT techniques has an over 2.0% probability of being more cost-effective. At a WTP threshold of $100,000/QALY, FIF, hybrid IMRT and MA-VMAT are more likely to be cost-effective than SOC with a probability of 59.2%, 72.3% and 72.6%, respectively.

**Discussion**

This study presents the most comprehensive cost-effectiveness analysis of seven WBRT techniques. Not only tumor control but also radiogenic side effects were included in the study. IMRT shows the highest baseline ICER which may due to its higher initial treatment cost and limited improvement of normal tissue sparing. FIF has the lowest baseline ICER which is mainly due to its low initial treatment cost and relatively lower probability of inducing cardiac toxicity compared with SOC. As shown in the PSAs, FIF, hybrid IMRT and MA-VMAT are more likely to be more cost-effective than SOC and other WBRT techniques at a WTP of $100,000/QALY, while SOC WBRT appeared to be more cost-effective than advanced WBRT techniques except for FIF at WTP of $50,000/QALY. Given the prevalence of breast cancer and continued growth of health care costs, results from this analysis will have a positive impact. Prior study has shown that up to 30% of the medical care spending in the US is unnecessary or inappropriate [48]. Moreover, study on Medicare patients found that higher spending was associated with more care but not better health outcomes [49]. The results from our analysis may benefit health care professionals and help choose the most cost-effective health intervention for breast cancer patients.

Radiotherapy is a crucial component of breast cancer treatment, and several studies have compared cost-effectiveness between different WBRT and accelerated partial breast irradiation (APBI) techniques. Shah et al. [18] reported that external beam APBI costs less and is more effective than hypofractionated WBRT after 90 days of the initial treatment. Another study by
their group [50] compared multiple APBI techniques with WBRT delivered with 3D-conformal therapy and IMRT, and showed that external beam APBI is more cost-effective than WBRT using 3D-conformal therapy, and all APBI techniques are more cost-effective than WBRT using IMRT. Sher et al. [17] compared the cost-effectiveness between WBRT, external beam and MammoSite (MS) APBI, and also concluded that external beam APBI is the most cost-effective strategy for early-stage breast cancer patients. However, not all lumpectomy patients are eligible for APBI, and the cost-effectiveness analysis of different advanced WBRT techniques is largely lacking. Sen et al. [51] compared no radiotherapy, conventional external beam WBRT and IMRT WBRT for women older than 70. They only considered tumor control, and they reported that IMRT would have to be substantially more effective in improving quality of life than conventional external beam therapy to be cost-effective. Because they did not include short-term or long-term side effects in their study, they used the increase of utility of baseline state to be a vague representation of improvement in quality of life. Our study shows that the risk of developing contralateral breast cancer may significantly affect the cost-effectiveness for advanced WBRT techniques, and contralateral breast cancer is directly related to quality of life for WBRT patients. Our study is therefore consistent with Sen et al. [51] and clearly suggests reducing irradiation of contralateral breast could be a key factor to make advanced WBRT technique more cost-effective. For SOC WBRT, considerable volumes of heart and ipsilateral lung are likely to receive high doses which may lead to radiation-related toxicities such as secondary lung cancer [52] and heart disease [40, 53]. The radiogenic side effects will not only affect patients’ quality of life, but also add further economic burden for WBRT patients. Advanced radiotherapy techniques could avoid high dose exposure to surrounding and underlying healthy tissues and improve the quality of life for the patients.

A previous study from our group evaluated cost-effectiveness of current SOC post-mastectomy radiotherapy (PMRT) and seven advanced PMRT techniques over 15 years [54]. It used a similar Markov model and showed that the model outcomes are most sensitive to the probability of developing cardiac toxicity for PMRT patients. As shown in the one-way analysis in this study, the cost-effectiveness of all WBRT techniques is most sensitive to the risk of developing contralateral breast cancer. The possible reason for this discrepancy is treatment target is much closer to heart for PMRT patients than for WBRT patients, which significantly increases the risks of heart toxicity and makes it a contributing factor to the cost-effectiveness of PMRT techniques. On the other hand, the risk of developing contralateral breast cancer for WBRT patients is much higher than for PMRT patients, which is mainly due to the relatively large field size used in WBRT to cover the whole ipsilateral breast and increased irradiation of the contralateral breast. Additionally, treating contralateral breast cancer will cost almost $3,000 more than treating heart toxicity (Table 2). Therefore, providing better sparing of contralateral breast is essential for advanced WBRT technique to be cost-effective.

Proton therapy was not included in this study. Although proton therapy has been shown to be a promising WBRT technique to reduce heart and lung dose [55, 56], it did not gain popularity due to its limited availability, multiple uncertainties [57, 58], possible skin toxicity [59, 60] and significantly higher cost. Another effective method to limit radiation dose to heart and lung is deep inspiration breath-hold (DIBH), which is particularly useful for treating patients with left-sided breast cancer [61, 62]. Macrie et al. [63] reported a DIBH program that is inexpensive to implement and has minimum influence on patient throughput. Chatterjee et al. [64] concluded that although DIBH requires significant resource commitments regarding person-hours, it is still more cost-effective due to the reductions in cardiac mortality. Comparing cost-effectiveness of various WBRT techniques for patients with DIBH is still lacking and will be investigated by our group in the near future. Hypofractionated WBRT is effective for selected early-stage breast cancer patients. It is more convenient for the patients and caregivers...
and can significantly cut treatment costs. However, hypofractionation is not the current SOC in our clinic or many other clinics in the US. Considering the cost calculations will be completely different, the outcome data for patients treated with hypofractionation are scarce, and existing dose-risk models are based on standard fractionated radiotherapy, we did not include those patients in this study. The cost-effectiveness evaluation of various techniques for hypofractionated WBRT patients will be investigated by our group in the future when more outcome data come out.

Our study has some limitations. First, we used well-defined dose-risk models to calculate probabilities of developing radiogenic late effects for advanced WBRT techniques because there is a lack of clinical outcome data. However, as shown in another study from our group [44], the calculated risks of cardiac toxicity and second cancers after SOC WBRT are in good agreement with the clinical outcomes, so we expect our calculated risks values for advanced WBRT techniques are also reasonable. Long-term clinical trial outcomes will be needed to validate the calculated outcomes for advanced WBRT techniques. Second, it’s difficult to assess the total costs of care for primary cancer or treatment-related side effects from the available literatures. As Campbell and Ramsey [65] point out, many studies ignored or truncated the duration of the continuing care period, or only focused on certain subpopulations, and many of them are quite dated and do not reflect changes in patterns of care. It is possible that the outcome and cost values used in our study contain uncertainties, but the comprehensive uncertainty analyses took these into account by varying each possible uncertain value over plausible ranges and assessing their impact on the final cost-effectiveness.

Conclusions

We evaluated cost-effectiveness of seven WBRT techniques. Based on calculated ICER values and comprehensive uncertainty analyses, FIF appears to be the most cost-effective approach for WBRT patients at a WTP threshold of $50,000/QALY, and hybrid IMRT and MA-VMAT might be the most cost-effective options at a WTP threshold of $100,000/QALY. Providing better sparing of contralateral breast is essential for advanced WBRT techniques to be cost effective.

Supporting information

S1 Fig. Tornado diagram of one-way analyses that compare SOC with (a) FIF, (b) Hybrid, (c) IMRT, (d) STD-VMAT, (e) NC-VMAT and (f) MA-VMAT. One-way sensitivity analysis examines the impact of variables on the outcomes (e.g., ICER) by changing a specific value over its uncertainty range while keeping all other variables constant at their baseline value. The dashed line represents the baseline ICER, and the width of the bars represents the change of ICER based on the uncertainty range of each variable. The wider the bar is, the more significant impact the variable has on the ICER value. P_: probability of developing certain radiogenic side effect using certain WBRT technique. Utility_: utility value for certain radiogenic side effect. Cost_: cost of treating certain radiogenic side effect. (DOCX)

S2 Fig. Cost-effectiveness acceptability curves that compare the cost-effectiveness of SOC and (a) FIF, (b) Hybrid, (c) IMRT, (d) STD-VMAT, (e) NC-VMAT and (f) MA-VMAT at different willingness to pay (WTP) thresholds. The data points indicate the percentage of iterations out of 100,000 iterations that were cost-effective at a given WTP threshold during probabilistic sensitivity analysis. The two dashed lines shown in the figures highlight the WTP threshold at 50,000 $/QALY and 100,000 $/QALY, respectively. (DOCX)
Author Contributions
Conceptualization: Rui Zhang.
Data curation: Yibo Xie.
Funding acquisition: Rui Zhang.
Investigation: Yibo Xie, Beibei Guo, Rui Zhang.
Methodology: Beibei Guo, Rui Zhang.
Project administration: Rui Zhang.
Software: Rui Zhang.
Supervision: Rui Zhang.
Validation: Beibei Guo.
Writing – original draft: Yibo Xie.
Writing – review & editing: Yibo Xie, Rui Zhang.

References
1. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005, 366:2087–2106. https://doi.org/10.1016/S0140-6736 (05)67887-7 PMID: 16360786
2. Halperin EC, Perez CA, Brady LW: *Perez and Brady’s Principles and Practice of Radiation Oncology*, 5th Edition. Philadelphia, PA: LWW; 2008.
3. RTOG: 0413: A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I or II breast cancer. 2011.
4. Cox JD, Ang KK: *Radiation Oncology: rationale, technique, results*. 9th ed. Philadelphia, PA: MOSBY ELSEVIER; 2010.
5. Lo YC, Yasuda G, Fitzgerald TJ, Urie MM: Intensity modulation for breast treatment using static multileaf collimators. *Int J Radiat Oncol Biol Phys* 2000, 46:187–194. https://doi.org/10.1016/s0360-3016 (99)00382-x PMID: 10656392
6. Farace P, Zucca S, Solia I, Fadda G, Durzu S, PorrSU, et al.: Planning hybrid intensity modulated radiation therapy for whole-breast irradiation. *Int J Radiat Oncol Biol Phys* 2012, 84:e115–122. https://doi.org/10.1016/j.ijrobp.2012.02.025 PMID: 22543199
7. Jeulink M, Dahele M, Meijnen P, Slotman BJ, Verbakel WF: Is there a preferred IMRT technique for left-breast irradiation? *J Appl Clin Med Phys* 2015, 16:5266. https://doi.org/10.1120/jacmp.v16i3.5266 PMID: 26103488
8. Mayo CS, Urie MM, Fitzgerald TJ: Hybrid IMRT plans—concurrently treating conventional and IMRT beams for improved breast irradiation and reduced planning time. *Int J Radiat Oncol Biol Phys* 2005, 61:922–932. https://doi.org/10.1016/j.ijrobp.2004.10.033 PMID: 15708276
9. Beckmann WA, Popescu CC, Patenaude VV, Wai ES, Olivotto IA: Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? *Int J Radiat Oncol Biol Phys* 2007, 69:918–924. https://doi.org/10.1016/j.ijrobp.2007.06.060 PMID: 17889273
10. Freedman GM, Anderson PR, Li J, Eisenberg DF, Hanlon AL, Wang L, et al.: Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. *Am J Clin Oncol* 2006, 29:66–70. https://doi.org/10.1097/01.coc.0000197861.09628.03 PMID: 16462506
11. Popescu CC, Olivotto IA, Beckmann WA, Ansbaeker W, Zavgorodni S, Shaffer R, et al.: Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes. *Int J Radiat Oncol Biol Phys* 2010, 76:287–295. https://doi.org/10.1016/j.ijrobp.2009.05.038 PMID: 19775832
12. Tsai PF, Lin SM, Lee SH, Yeh CY, Huang YT, Lee CC, et al.: The feasibility study of using multiple partial volumetric-modulated arcs therapy in early stage left-sided breast cancer patients. *J Appl Clin Med Phys* 2012, 13:3806. https://doi.org/10.1120/jacmp.v13i5.3806 PMID: 22955645
13. Xie Y, Bourgeois D, Guo B, Zhang R: Postmastectomy radiotherapy for left-sided breast cancer patients: Comparison of advanced techniques. *Med Dosim* 2020, 45:34–40. doi:https://doi.org/10.1016/j.meddos.2019.04.005 PMID: 31129035

14. Ruben JD, Smith R, Lancaster CM, Haynes M, Jones P, Panettieri V: Constituent components of out-of-field scatter dose for 18-MV intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy: a comparison with 6-MV and implications for carcinogenesis. *Int J Radiat Oncol Biol Phys* 2014, 90:645–653. doi:https://doi.org/10.1016/j.ijrobp.2014.05.052 PMID: 25084609

15. Hall EJ, Wuu CS: Radiation-induced second cancers: the impact of 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys* 2003, 56:83–88. doi:https://doi.org/10.1016/s0360-3016(03)00073-7 PMID: 12694826

16. Marotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML: Projections of the cost of cancer care in the United States: 2010–2020. *J Natl Cancer Inst* 2011, 103:117–128. doi:https://doi.org/10.1093/jnci/dj495 PMID: 21228314

17. Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS: Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. *Int J Radiat Oncol Biol Phys* 2009, 74:440–446. doi:https://doi.org/10.1016/j.ijrobp.2008.08.015 PMID: 18993542

18. Shah C, Ward MC, Tendulkar RD, Cherian S, Vicini F, Singer ME: Cost and Cost-Effectiveness of Image Guided Partial Breast Irradiation in Comparison to Hypofractionated Whole Breast Irradiation. *Int J Radiat Oncol Biol Phys* 2019, 103:397–402. doi:https://doi.org/10.1016/j.ijrobp.2018.09.021 PMID: 30253326

19. Sher DJ, Wittenberg E, Taghian AG, Bellon JR, Punglia RS: Partial breast irradiation versus whole breast radiotherapy for early-stage breast cancer: a decision analysis. *Int J Radiat Oncol Biol Phys* 2008, 70:469–476. doi:https://doi.org/10.1016/j.ijrobp.2007.08.054 PMID: 17967514

20. Grosse SD: Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. *Med Decis Making* 2011, 305:1806–1807. doi:https://doi.org/10.1016/j.meddec.2011.566 PMID: 21540426

21. Neumann PJ: What next for QALYs? *JAMA* 2011, 305:1806–1807. doi:https://doi.org/10.1001/jama.2011.566 PMID: 21540426

22. Colzani E, Johansson AL, Liljegren A, Foukakis T, Clements M, Adolfsson J, et al.: Time-dependent additional benefits of incorporating smoking cessation interventions. *PLoS One* 2013, 8:e71379. doi:https://doi.org/10.1371/journal.pone.0071379 PMID: 23940744

23. Ruben JD, Smith R, Lancaster CM, Haynes M, Jones P, Panettieri V: Constituent components of out-of-field scatter dose for 18-MV intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy: a comparison with 6-MV and implications for carcinogenesis. *Int J Radiat Oncol Biol Phys* 2014, 90:645–653. doi:https://doi.org/10.1016/j.ijrobp.2014.05.052 PMID: 25084609

24. Arias E, Xu J: United States Life Tables, 2015. *Natl Vital Stat Rep* 2016, 64:1–82. doi:https://doi.org/10.1001/jnci.2014.9 PMID: 24434426

25. Henson KE, McGale P, Taylor C, Darby SC: Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. *Br J Cancer* 2013, 108:179–182. doi:https://doi.org/10.1038/bjc.2013.4 PMID: 23257897

26. Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, et al.: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. *J Natl Cancer Inst Monogr* 2010, 2010:162–177. doi:https://doi.org/10.1093/jncimono/7gg039 PMID: 20956824

27. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG: Retrospective cost-effectiveness analysis of screening mammography. *J Natl Cancer Inst* 2006, 98:774–782. doi:https://doi.org/10.1093/jnci/djj210 PMID: 16757702

28. Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jonsson B, Glimelius B: Economic evaluation of proton therapy in the treatment of breast cancer. *Radiother Oncol* 2005, 75:179–185. doi:https://doi.org/10.1016/j.radonc.2005.03.006 PMID: 15885828

29. Sullivan PW, Ghuschchyan V: Preference-Based EQ-5D index scores for chronic conditions in the United States. *Med Decis Making* 2006, 26:410–420. doi:https://doi.org/10.1177/0272989X06290495 PMID: 16855129

30. Villanti AC, Jiang Y, Abrams DB, Pyenson BS: A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. *PLoS One* 2013, 8:e71379. doi:https://doi.org/10.1371/journal.pone.0071379 PMID: 23940744

31. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
Cost effectiveness analysis of whole breast radiotherapy

34. Roberts A, Habibi M, Frick KD: Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer. *Ann Surg Oncol* 2014, 21:2209–2217. https://doi.org/10.1245/s10434-014-3588-7 PMID: 24633665

35. Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, et al: Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBiS). *Lung Cancer* 2018, 124:298–309. https://doi.org/10.1016/j.lungcan.2018.06.007 PMID: 29961557

36. Schwarzkopf L, Wacker M, Holle R, Leidl R, Gunster C, Adler JB, et al: Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens. *Lung Cancer* 2015, 90:274–280. https://doi.org/10.1016/j.lungcan.2015.09.006 PMID: 26384433

37. Keusters WR, de Weger VA, Hovels A, Schellens JHM, Frederik GWJ: Changing costs of metastatic non small cell lung cancer in the Netherlands. *Lung Cancer* 2017, 114:56–61. https://doi.org/10.1016/j.lungcan.2017.10.005 PMID: 29173766

38. Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC: Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. *Value Health* 2008, 11:213–220. https://doi.org/10.1111/j.1524-4733.2007.00226.x PMID: 18380633

39. National Research Council. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII—Phase 2. Washington, DC: National Academies Press; 2006.

40. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013, 368:987–998. https://doi.org/10.1056/NEJMo1209825 PMID: 23484825

41. Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA* 2007, 297:611–619. https://doi.org/10.1001/jama.297.6.611 PMID: 17299196

42. Roychoudhuri R, Evans H, Robinson D, Moller H: Radiation-induced malignancies following radiotherapy for breast cancer. *Br J Cancer* 2004, 91:868–872. https://doi.org/10.1038/sj.bjc.6602084 PMID: 15292931

43. Yadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor RK: Second primary in the contralateral breast after treatment of breast cancer. *Radiother Oncol* 2008, 86:171–176. https://doi.org/10.1016/j.radonc.2007.10.002 PMID: 17961777

44. Xie Y, Bourgeois D, Guo B, Zhang R: Comparison of conventional and advanced radiotherapy techniques for left-sided breast cancer after breast conserving surgery. *Med Dosim* 2020, 45:e9–e16. https://doi.org/10.1016/j.meddos.2020.05.004 PMID: 32646715

45. Breast Cancer Treatment Outcome Calculator: http://www.lifemath.net/cancer/breastcancer/therapy/index.php

46. Michaelson JS, Chen LL, Bush D, Fong A, Smith B, Younger J: Improved web-based calculators for predicting breast carcinoma outcomes. *Breast Cancer Res Treat* 2011, 128:827–835. https://doi.org/10.1007/s10549-011-1366-9 PMID: 21327471

47. Briggs A: Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. *Value Health* 2005, 8:1–2. https://doi.org/10.1111/j.1524-4733.2005.08101.x PMID: 15841888

48. Garber A, Goldman DP, Jena AB: The promise of health care cost containment. *Health Aff (Millwood)* 2007, 26:1545–1547. https://doi.org/10.1377/hilffact.26.6.1545 PMID: 17978370

49. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL: The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. *Ann Intern Med* 2003, 138:288–298. https://doi.org/10.1036/s0003-4819-138-4-200302180-00007 PMID: 12585826

50. Shah C, Lanni TB, Saini H, Nanavati A, Wilkinson JB, Badiyan S, et al: Cost-efficacy of accelerated partial-breast irradiation compared with whole-breast irradiation. *Breast Cancer Res Treat* 2013, 138:127–135. https://doi.org/10.1007/s10549-013-2412-6 PMID: 23329353

51. Sen S, Wang SY, Soulsor PR, Frick KD, Long JB, Roberts KB, et al.: Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer. *J Natl Cancer Inst* 2014, 106:duu008. https://doi.org/10.1093/jnci/dju008 PMID: 24598714

52. Inskip PD, Stovall M, Flannery JT: Lung cancer risk and radiation dose among women treated for breast cancer. *J Natl Cancer Inst* 1994, 86:983–988. https://doi.org/10.1093/jnci/86.13.983 PMID: 8007020

53. Little MP, Zablotka LB, Lipshtul SE: Ischemic heart disease after breast cancer radiotherapy. *N Engl J Med* 2013, 368:2523–2524. https://doi.org/10.1056/NEJMc1304601 PMID: 23802524
54. Xie Y, Guo B, Zhang R: Cost-effectiveness analysis of advanced radiotherapy techniques for post-mastectomy breast cancer patients. *Cost Eff Resour Alloc* 2020, 18:26. https://doi.org/10.1186/s12962-020-00222-y PMID: 32774176

55. Ares C, Khan S, Macartain AM, Heuberger J, Goitein G, Gruber G, et al.: Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? *Int J Radiat Oncol Biol Phys* 2010, 76:685–697. https://doi.org/10.1016/j.ijrobp.2009.02.062 PMID: 19615828

56. Lin LL, Vennarini S, Dimoffe A, Ravanelli D, Shillington K, Batra S, et al.: Proton beam versus photon beam dose to the heart and left anterior descending artery for left-sided breast cancer. *Acta Oncol* 2015, 54:1032–1039. https://doi.org/10.3109/0284186X.2015.1011756 PMID: 25789715

57. Lomax AJ: Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions. *Phys Med Biol* 2008, 53:1043–1056. https://doi.org/10.1088/0031-9155/53/4/015 PMID: 18263957

58. Lomax AJ: Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. *Phys Med Biol* 2008, 53:1027–1042. https://doi.org/10.1088/0031-9155/53/4/014 PMID: 18263956

59. Kozak KR, Smith BL, Adams J, Kornmehl E, Katz A, Gadd M, et al.: Accelerated partial-breast irradiation using proton beams: initial clinical experience. *Int J Radiat Oncol Biol Phys* 2006, 66:691–698. https://doi.org/10.1016/j.ijrobp.2006.06.041 PMID: 17011445

60. Liang X, Bradley JA, Zheng D, Rutenberg M, Yeung D, Mendenhall N, et al.: Prognostic factors of radiation dermatitis following passive-scattering proton therapy for breast cancer. *Radiat Oncol* 2018, 13:72. https://doi.org/10.1186/s13014-018-1004-3 PMID: 29673384

61. Latty D, Stuart KE, Wang W, Ahern V: Review of deep inspiration breath-hold techniques for the treatment of breast cancer. *J Med Radiat Sci* 2015, 62:74–81. https://doi.org/10.1002/jmrs.96 PMID: 26229670

62. Dell'Oro M, Giles E, Sharkey A, Borg M, Connell C, Bezak E: A Retrospective Dosimetric Study of Radiotherapy Patients with Left-Sided Breast Cancer; Patient Selection Criteria for Deep Inspiration Breath Hold Technique. *Cancers (Basel)* 2019, 11. https://doi.org/10.3390/cancers1122031 PMID: 31882925

63. Macrie BD, Donnelly ED, Hayes JP, Gopalakrishnan M, Philip RT, Reczek J, et al.: A cost-effective technique for cardiac sparing with deep inspiration-breath hold (DIBH). *Phys Med* 2015, 31:733–737. https://doi.org/10.1016/j.ejmp.2015.06.006 PMID: 26117242

64. Chatterjee S, Chakraborty S, Moses A, Nallathambi C, Mahata A, Mandal S, et al.: Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis. *Pract Radiat Oncol* 2018, 8:382–387. https://doi.org/10.1016/j.prro.2018.03.007 PMID: 29699893

65. Campbell JD, Ramsey SD: The costs of treating breast cancer in the US: a synthesis of published evidence. *Pharmacoconomics* 2009, 27:199–209. https://doi.org/10.2165/00019053-200927030-00003 PMID: 19354340